Legend Biotech shares are trading higher after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $65 to $85.
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained an Overweight rating on Legend Biotech and raised its price target from $65 to $85. This has resulted in Legend Biotech's shares trading higher.
July 20, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech's shares are trading higher after Morgan Stanley maintained an Overweight rating and raised its price target from $65 to $85.
The news of Morgan Stanley maintaining an Overweight rating and raising its price target for Legend Biotech is a positive signal for the company. This indicates that Morgan Stanley has a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100